Haifeng Wang
Anhui Province Key Laboratory Of Translational Cancer Research
Bengbu, 233030, China
Bengbu, 233030, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
The N-terminal polypeptide derived from vMIP-II exerts its anti-tumor activity in human breast cancer by regulating lncRNA SPRY4-IT1.
Journal: Bioscience reports
Published: March 19, 2018
NT21MP negatively regulates paclitaxel-resistant cells by targeting miR‑155‑3p and miR‑155-5p via the CXCR4 pathway in breast cancer.
Journal: International journal of oncology
Published: January 31, 2018
CXC chemokine receptor 4 regulates breast cancer cell cycle through S phase kinase associated protein 2
Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: December 20, 2017
Effects of lncRNA RP11-770J1.3 and TMEM25 expression on paclitaxel resistance in human breast cancer cells
Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: December 20, 2017
Anticancer Effects of Resveratrol-Loaded Solid Lipid Nanoparticles on Human Breast Cancer Cells.
Journal: Molecules (Basel, Switzerland)
Published: September 16, 2017
N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
Journal: International journal of oncology
Published: March 24, 2017
Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer.
Journal: Cell death & disease
Published: February 20, 2017
Showing 1-8 of 8
Last Updated: 09/26/2026